Block Listing - Six Monthly Review
April 11 2008 - 6:00AM
UK Regulatory
Block Listing - Six Monthly Review
+-------------------------------------------------------------------+
| Name of Company: | Hikma Pharmaceuticals |
| | PLC |
|-----------------------------------------+-------------------------|
| Name of scheme: | Hikma Pharmaceuticals |
| | PLC 2004 Stock Option |
| | Plan |
|-----------------------------------------+-------------------------|
| Period of return: | 6 October 2007 |
| From: | To: 11 April 2008 |
|-----------------------------------------+-------------------------|
| Balance under block scheme: | 1,405,400 ordinary |
| | shares of 10 pence each |
|-----------------------------------------+-------------------------|
| The amount by which the block scheme | 2,432,400 ordinary |
| has been increased, if the scheme has | shares of 10 pence |
| been increased since the date of the | |
| last return: | |
|-----------------------------------------+-------------------------|
| Number of securities issued/allotted | 1,856,200 ordinary |
| under scheme during period: | shares of 10 pence each |
|-----------------------------------------+-------------------------|
| Balance under scheme not yet issued/ | 1,981,600 ordinary |
| allotted at end of period | shares of 10 pence each |
|-----------------------------------------+-------------------------|
| Number and class of securities | 166,537,951 ordinary |
| originally listed and the date of | shares of 10 pence each |
| admission | originally listed on 1 |
| | November 2005 |
|-----------------------------------------+-------------------------|
| Total number of securities in issue at | 188,307,607 ordinary |
| the end of the period | shares of 10 pence each |
+-------------------------------------------------------------------+
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC +44 20 7399 2760
Henry Knowles, Company Secretary
Susan Ringdal, Investor Relations Director
Notes to Editors
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed pharmaceutical
products. Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics". Hikma's operations are based
principally in the Middle East and North Africa ("MENA") region,
where it is a market leader and sells across 17 countries, the United
States and Europe. In 2007, the Group achieved revenues of $449
million (2006 $317 million) and profit attributable to shareholders
of $63 million (2006 $55 million). For news and other information,
please visit www.hikma.com .
- ---END OF MESSAGE---
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024